$7.22
6.65% yesterday
Nasdaq, Aug 18, 10:19 pm CET
ISIN
US87583X1090
Symbol
TNGX

Tango Therapeutics Inc Stock price

$7.22
+0.45 6.65% 1M
+4.79 197.12% 6M
+4.13 133.66% YTD
-3.46 32.40% 1Y
+2.22 44.40% 3Y
-3.01 29.42% 5Y
-3.01 29.42% 10Y
-3.01 29.42% 20Y
Nasdaq, Closing price Mon, Aug 18 2025
+0.45 6.65%
ISIN
US87583X1090
Symbol
TNGX
Industry

Key metrics

Basic
Market capitalization
$761.0m
Enterprise Value
$580.2m
Net debt
positive
Cash
$180.8m
Shares outstanding
110.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
31.3 | 26.2
EV/Sales
23.9 | 20.0
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
63.3%
Return on Equity
-65.2%
ROCE
-79.5%
ROIC
-506.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$24.3m | $29.0m
EBITDA
$-154.8m | $-176.8m
EBIT
$-157.3m | $-168.4m
Net Income
$-145.6m | $-152.9m
Free Cash Flow
$-149.6m
Growth (TTM | estimate)
Revenue
-42.8% | -31.1%
EBITDA
-18.9% | -23.6%
EBIT
-18.6% | -15.7%
Net Income
-24.4% | -17.4%
Free Cash Flow
-24.3%
Margin (TTM | estimate)
Gross
-
EBITDA
-637.1% | -609.7%
EBIT
-647.3%
Net
-599.1% | -527.4%
Free Cash Flow
-615.8%
More
EPS
$-1.3
FCF per Share
$-1.3
Short interest
24.2%
Employees
155
Rev per Employee
$270.0k
Show more

Is Tango Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Tango Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Tango Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Tango Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Tango Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
24 24
43% 43%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 45 45
12% 12%
186%
- Research and Development Expense 136 136
1% 1%
562%
-155 -155
19% 19%
-637%
- Depreciation and Amortization 2.49 2.49
0% 0%
10%
EBIT (Operating Income) EBIT -157 -157
19% 19%
-647%
Net Profit -146 -146
24% 24%
-599%

In millions USD.

Don't miss a Thing! We will send you all news about Tango Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tango Therapeutics Inc Stock News

Neutral
The Motley Fool
13 days ago
Tango (TNGX) Q2 Revenue Drops 52%
Neutral
GlobeNewsWire
13 days ago
– First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors – – First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5 inhibitor in development for glioblastoma – BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and deliverin...
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selectiv...
More Tango Therapeutics Inc News

Company Profile

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Barbara Weber
Employees 155
Founded 2017
Website www.tangotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today